Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBT (2016 - 2025)

Agios Pharmaceuticals' EBT history spans 14 years, with the latest figure at -$109.1 million for Q4 2025.

  • For Q4 2025, EBT fell 3.47% year-over-year to -$109.1 million; the TTM value through Dec 2025 reached -$415.6 million, down 158.14%, while the annual FY2025 figure was -$413.8 million, 157.63% down from the prior year.
  • EBT reached -$109.1 million in Q4 2025 per AGIO's latest filing, down from -$103.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.0 billion in Q3 2024 to a low of -$112.5 million in Q2 2025.
  • Average EBT over 5 years is -$39.4 million, with a median of -$92.0 million recorded in 2022.
  • Peak YoY movement for EBT: soared 1196.14% in 2024, then plummeted 110.33% in 2025.
  • A 5-year view of EBT shows it stood at -$98.6 million in 2021, then increased by 5.98% to -$92.7 million in 2022, then fell by 3.51% to -$95.9 million in 2023, then decreased by 9.86% to -$105.4 million in 2024, then decreased by 3.47% to -$109.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's EBT are -$109.1 million (Q4 2025), -$103.4 million (Q3 2025), and -$112.5 million (Q2 2025).